Umbilical cord blood (CB) remains an important alternative hematopoietic stem cell source for patients in need of an allogeneic transplant, strengthened by decreased matching requirements at HLA-A, -B and -DRB1 compared to an adult donor.
1,2 A minimum total nucleated cell (TNC) dose of ⩾ 2.5 × 10 7 cells/kg is necessary to decrease the risk of engraftment failure in CB transplants. 1, 3 To achieve this TNC, two CB units are often required in adults. Following double unit cord blood transplant (DUCBT), only one of the two units typically provides long-term engraftment. The factors predicting which unit predominates remain elusive. Total cell dose, order of infusion and HLA-A, -B and -DRB1 matching have been assessed without definitive results; however, recent data suggest that the unit with the larger CD34+ cell dose may be predictive. [4] [5] [6] Recipients of an HLA-C-mismatched unit experience increased transplant-related mortality (TRM) compared to HLA-C-matched single CB transplants, but its impact on outcomes in DUCBT recipients has not been widely studied. 5 As the predominating unit has a sustained immune response or 'argument' against the non-predominating unit, HLA mismatching between the two CB units may affect transplant-associated outcomes. 7 Therefore, we retrospectively examined the effect of HLA-C and overall HLA matching on unit dominance and donor-donor (D-D) interactions on DUCBT outcomes.
Patients at Moffitt Cancer Center receiving a DUCBT for any hematologic malignancy from 13 November, 2009, through 30 August, 2013, with available HLA-C typing receiving myeloablative (MAC) (n = 14) or reduced intensity conditioning (RIC) (n = 40) were included. CB units were selected using a minimum pre-freeze celldose threshold of 1.5 × 10 7 TNC/kg per unit and typed at intermediate resolution for HLA-A, -B, -C and high resolution at -DRB1. 4 Priority for HLA-DRB1 matching was emphasized, and CB units were selected matching to the donor with a minimum of 5/8 HLA loci. No patients had donor specific antibodies.
Patient-related variables included age, gender, hematopoietic cell transplant comorbidity index (HCT-CI) and CMV serology. Disease-related variables included type, American Society of Blood and Marrow Transplant Disease Classification and Response 2014 (ASBMT RFI 2014) disease risk, number of prior therapies, conditioning intensity, anti-thymocyte globulin (ATG) and GvHD prophylaxis regimen. Transplant-related variables included the order of CB unit infusions and unit TNC, CD34+ and CD3+ cell doses.
For the dominant unit analyses, peripheral blood and bone marrow chimerism studies obtained between day 21 and 28 were reviewed; day 100 studies confirmed unit dominance. A unit was defined as predominating if ⩾ 90% of CD3, CD33 and bone marrow populations were of the same CB unit; otherwise, patients were considered as mixed chimeras.
Recipients receiving one CB unit HLA-C matched paired with an HLA-C-mismatched unit were examined for impact on unit dominance. The impact of overall HLA matching was assessed by comparing recipients receiving one CB unit HLA mismatched at ⩽ 2 loci paired with a CB unit mismatched at 42 loci. The effects of HLA-C and overall HLA-match on unit dominance were calculated by the Fisher exact test. Unit cell doses and order of infusion were assessed for association with the predominating unit using the Mann-Whitney test. 8 D-D unit interactions were assessed by comparing recipients receiving CB pairs matched at HLA-C to those CB pairs mismatched at HLA-C. Overall D-D HLA matching was assessed by comparing recipients with CB pairs having ⩽ 2 of 8 HLA mismatches to those receiving CB pairs having 42 HLA mismatches. For the D-D analyses, outcomes of neutrophil and platelet engraftment, acute and chronic GvHD, infections, transplant-related mortality (TRM) and overall survival (OS) were summarized by the cumulative incidence estimate, analyzed at last follow-up, with death as a competing risk. Median time to event(s) was compared using the Mann-Whitney test. Neutrophil engraftment, platelet engraftment, and acute and chronic GvHD used standard definitions. [9] [10] [11] Post-transplant infection density in the first 100 days was calculated for bacterial, fungal and common viral infections; adenovirus was excluded due to the low frequency (n = 3). 12 TRM was defined as death while in continuous remission from primary disease and OS as the time to death from any cause, calculated using the Kaplan-Meier estimator and the variance estimated by Greenwood's formula. 13 Due to the limited number of patients and events, univariate analyses were performed using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA) and SAS Program 9.1 (SAS Institute, Cary, NC, USA).
Fifty-four patients met the criteria for analysis. For all comparisons, baseline characteristics of the patient populations were not statistically different in regards to disease status, lines of therapy before transplant, CIBMTR relapse risk, HCT-comorbidity index, pre-transplant CMV positivity, conditioning regimens and total cell dose (results not shown).
Seven (13%) patients (MAC = 1, RIC = 6) demonstrated a persistent mixed chimera beyond day 100 and 6 (11%) patients (MAC = 1, RIC = 5) died before confirmatory chimerism assessments; a total of 41 patients were available for the dominant unit analyses (Table 1) . Thirteen patients received one CB unit HLA-C matched to the recipient paired with one CB unit HLA mismatched to the recipient. The unit HLA-C matched to the recipient predominated in 69% (n = 9, P = 0.12). Fifteen patients received one CB unit mismatched at ⩽ 2 of 8 HLA loci to the recipient and paired with a second CB unit mismatched at 42 HLA loci. For these patients, the CB unit mismatched to the recipient at ⩽ 2 of 8 HLA loci predominated in 67% (n = 10, P = 0.14). To assess cell dose, patients receiving two units with similar TNC, defined as a difference ⩽ 0.3 × 10 7 TNC/kg, were excluded (n = 13). For CD34+ and CD3+ cell doses, recipients of units with a difference ⩽ 0.03 × 10 5 cells/kg or with unknown counts were also excluded (n = 14, n = 8). Although not significant, only a larger CD34+ cell dose appeared important (Table 1) . Unit order of infusion was not predictive of unit engraftment (data not shown).
Irrespective of the subsequent predominating unit, HLA matching between the donor CB units (D-D) was analyzed. Patients with inter-unit HLA-C matching (n = 14) were compared to those receiving units HLA-C mismatched (n = 40) to each other. Patients receiving units mismatched at ⩽ 2 loci (n = 19) were compared to those receiving units mismatched at 42 loci (n = 35). Neither neutrophil nor platelet engraftment differed based on inter-unit HLA-C matching or overall HLA matching. The cumulative incidence and median onset of grades II-IV acute GvHD by day 100 and moderate/severe chronic GvHD by 1 year were similar in patients with HLA-C-matched donor units compared to those receiving HLA-C-mismatched donor units. Similarly, acute and chronic GvHD did not differ in patients receiving D-D units with ⩽ 2 HLA mismatches compared to those receiving D-D units with 42 mismatches. TRM, OS and relapse were not impacted by inter-unit HLA-C matching or overall HLA matching. The densities of bacterial, fungal and viral infections were not statistically different comparing inter-unit HLA-C match versus mismatch, although the rate of bacterial infections by day 100 was non-significantly less for recipients of HLA-C intermatched units (0.55 versus 1.05 infections/patient/100 days). Patients receiving D-D units with ⩽ 2 HLA mismatches compared to those receiving units with 42 mismatches also had similar infection densities. Table 2 reports data for inter-unit HLA-C matching; overall HLA-matching data is not shown.
We sought to determine if HLA-C matching influences unit dominance following DUCBT. Furthermore, we examined if HLA-C matching influences outcomes through potential CB unit Infection density, overall score: total number of infections/total number of days at risk for the first 100 days × 100 days. Abbreviations: CB = cord blood; CI = confidence of interval; TNC = total nucleated cell.
Letter to the Editor 'arguments'. The retrospective nature of the analysis and the limited CB pairings available limited this assessment. Despite the limitation, there was a suggestion that CB units HLA-C matched to the recipient may predominate over mismatched units. A trend towards dominance in the better overall HLA matched unit was also identified. As prior studies have not suggested HLA-A, -B and -DRB1 importance on unit dominance, this suggests that HLA-C matching may influence the 'winning' unit. A larger cohort is necessary to address. Cell dose may also contribute to unit dominance. Although CD3+ cell dose was not significant in our patient population, there was a trend towards dominance in units with a larger CD34+ cell dose. Recently, a study demonstrated that for patients receiving a DUCBT with CB from Netcord-FACT centers, the unit with the higher CD34+ cell dose tended to predominate. 6 Our data demonstrate a trend towards fewer bacterial infections for patients receiving inter-unit HLA-C-matched CB units. Inter-unit HLA-C and overall HLA match may have other implications in DUCBT recipients. The complexity of natural killer cell expansion and activating and inhibitory activities of killer immunoglobulin receptor (KIR) and HLA may provide a means of early immune activity and protection against infection for the recipient. 14 In CB recipients, the rate of natural killer expansion is larger compared to other donor sources. 15 CB recipients who have natural killer cell reconstitution with differentiation into a cytotoxic population had superior OS compared to those who do not.
14 A larger cohort is needed to investigate KIR typing as well as study the complex inter-unit immune interactions.
